RX Pharmatech

22nd Century Group, Inc. (NASDAQ: XXII) net revenue for the Q4 2022 was $19.2 million, an increase of 141.3% from $8 million in Q4 2021. Q4 2022 Financial Highlights Gross loss was $646,000, an unfavorable decrease of 379.7% compared to gross profit of $231,000 in the prior year period. Net...